PLOS

ACTREC Researchers Show Cancer Treatments May be Promoting its Spread

Retrieved on: 
Thursday, March 28, 2024
Research, Education, ACTREC, Glomus tumor, Neoplasm, DNA, Mouse, PLOS One, Radiation, Protein, Treatment, PLOS, Blood, Lymphatic system, Metastasis

MUMBAI, India, March 28, 2024 /PRNewswire/ -- Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing metastasis remains a major goal in oncology.

Key Points: 
  • In a step towards these efforts, Prof. Indraneel Mittra from the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India, has shed light on what causes metastasis.
  • Their findings, published in PLOS One result from experiments in mice grafted with human breast cancer cells (xenografts) to induce cancer.
  • Prof. Mittra concludes,"Future long-term experiments should explore whether cfChP-deactivating agents given concurrently with anti-cancer treatments could help prevent metastatic spread.
  • When used as adjuncts to cancer treatment, these agents would have the added advantage of preventing some of the toxic side effects of chemotherapy and radiotherapy."

ACTREC Researchers Show Cancer Treatments May be Promoting its Spread

Retrieved on: 
Thursday, March 28, 2024
Research, Education, ACTREC, Glomus tumor, Neoplasm, DNA, Mouse, PLOS One, Radiation, Protein, Treatment, PLOS, Blood, Lymphatic system, Metastasis

MUMBAI, India, March 28, 2024 /PRNewswire/ -- Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing metastasis remains a major goal in oncology.

Key Points: 
  • In a step towards these efforts, Prof. Indraneel Mittra from the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India, has shed light on what causes metastasis.
  • Their findings, published in PLOS One result from experiments in mice grafted with human breast cancer cells (xenografts) to induce cancer.
  • Prof. Mittra concludes,"Future long-term experiments should explore whether cfChP-deactivating agents given concurrently with anti-cancer treatments could help prevent metastatic spread.
  • When used as adjuncts to cancer treatment, these agents would have the added advantage of preventing some of the toxic side effects of chemotherapy and radiotherapy."

Global Journal Observatory: Better Understanding the Research Ecosystem

Retrieved on: 
Monday, March 4, 2024
Beijing Normal University, Publishing, Research, COPE, Information school, IMR, PLOS, Science and Technology Daily, Multimedia, SAGE Publishing, Science, Culture, Sale, Leiden University, University of Sheffield, Alphonse, Springer Nature, Perception, University, Information science, Factorization of polynomials, Improper integral, IOP Publishing, Organization, Journal, Thelwall, Civilization, Publication, Environment, Management

BEIJING, March 4, 2024 /PRNewswire/ -- Ronald Rousseau, the Co-Editor-in-Chief of the JDIS, shared his insights as follow:  

Key Points: 
  • Science and Technology Daily has launched a new column, Global Journal Observatory, with the National Science Library of the Chinese Academy of Sciences.
  • For the sake of better science, the JDIS has initiated a series of activities to respond to and reverse this situation.
  • During the event, a memorandum of understanding was signed, signaling the collaborative effort required to safeguard the integrity of scientific research.
  • All of these initiatives serve our ultimate goal, that is, enabling researchers to publish the best possible scientific research to create a better life.

Maxwell Healthcare Associates, Hospice Dynamix, and Medalogix Announce Partnership

Retrieved on: 
Tuesday, February 20, 2024
Natural language processing, Hospice, AI, Intelligence, PLOS, Life, Entrepreneurship, MHA, Medicare, Health, Organization, Patient, Machine learning, Partnership, Nursing

SHOREVIEW, Minn., Feb. 20, 2024 /PRNewswire/ -- Maxwell Healthcare Associates (MHA), a leading provider in the post-acute space with an average of 20 years of experience, is proud to announce a groundbreaking partnership with Hospice Dynamix, and Medalogix.

Key Points: 
  • SHOREVIEW, Minn., Feb. 20, 2024 /PRNewswire/ -- Maxwell Healthcare Associates (MHA), a leading provider in the post-acute space with an average of 20 years of experience, is proud to announce a groundbreaking partnership with Hospice Dynamix, and Medalogix.
  • "We are thrilled to embark on this tripartite partnership with Hospice Dynamix and Medalogix," said Jennifer Maxwell, Co-Founder and CEO of Maxwell Healthcare Associates (MHA).
  • Terry Swatley, CEO at Hospice Dynamix, expressed enthusiasm about joining forces with Maxwell Healthcare Associates (MHA) and Medalogix to serve the hospice industry.
  • By leveraging the collective strengths and expertise of Maxwell Healthcare Associates, Hospice Dynamix, and Medalogix, the organizations aim to transform the hospice care landscape and improve outcomes for patients and their families.

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

Retrieved on: 
Tuesday, February 6, 2024
PLOS One, SNAP, Synapse, CMO, Cognition, Microscopy, FRET, University, Protein, PLOS, Therapy, Brain, Biology, Prion, Translational Neurodegeneration, TMEM97, Doctor of Philosophy, Medical imaging

Results detected TMEM97, a protein component of the σ-2 receptor complex, in close proximity to cellular prion protein (PrPc) on Alzheimer’s brain synapses.

Key Points: 
  • Results detected TMEM97, a protein component of the σ-2 receptor complex, in close proximity to cellular prion protein (PrPc) on Alzheimer’s brain synapses.
  • These findings support the hypothesis that these receptor proteins may form a complex on the synapse surface with Aβ oligomers binding to one or both proteins.
  • “Previous work indicated that Aβ oligomers damage synapses, but until now it was not possible to know which proteins bind toxic forms of Aβ in human synapses.
  • Importantly, this FRET signal is reduced in CT1812-treated mice, suggesting that CT1812 caused the release of Aβ oligomers from their binding site and prevented them from re-binding.

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

Retrieved on: 
Wednesday, January 31, 2024
Multiple sclerosis, Movement, Poster, GM1 gangliosidoses, Neuroprotection, Enamine, Workflow, SAD, AFL, GM1, ChromeOS, Clinical trial, Research, PLOS, Neuroinflammation, Biomarker, Patient, Safety, Ferdinand Magellan, FDA, Drug discovery, Organization, Neurodegenerative disease, AbbVie, Dopamine, Disease, Protein, Therapy, Acquisition, Merck, Letter, Glucocerebrosidase, GBA1, GLB1, University, Parkinson's disease, ALS, Plasma, Conference, Caraway, Pharmaceutical industry

In 2023, we advanced GT-02287 through preclinical development and initiated the company’s first clinical trial in September 2023 on time and on plan.

Key Points: 
  • In 2023, we advanced GT-02287 through preclinical development and initiated the company’s first clinical trial in September 2023 on time and on plan.
  • The dose escalation of the SAD phase is underway, and the MAD phase of the study is expected to begin in Q1 2024.
  • In 2023, we made several data presentations of results of our GBA1 program in preclinical models of Parkinson’s disease and Alzheimer’s disease.
  • Xavi is leaving the world of academia as a professor at the University of Barcelona and his part-time engagement with Gain to join a major pharmaceutical company.

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Retrieved on: 
Thursday, January 25, 2024
PP, Nephrology, Patient, Therapy, Stanford University Medical Center, OLE, PLOS, UPCR, Safety, Hematuria, Disease, Immunoglobulin A, E pluribus unum, EGFR, Pharmaceutical industry

BRISBANE, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced positive 72-week data from the open label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN). In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in IgAN.

Key Points: 
  • In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in IgAN.
  • “Data from the OLE show the consistent and sustained reductions of Gd-lgA1, hematuria, and UPCR, as well as the stability of eGFR over 72 weeks in participants with IgAN.
  • “We are thrilled to present this package of positive new data from the OLE of the Phase 2b ORIGIN clinical trial during our R&D Day, which will be held today in New York.
  • The R&D Day presentation, which includes the OLE 72-Week data slides and commentary, will be available on the Company’s website at the Investor Calendar .

Koneksa Announces New Multi-Domain Model for Functional Status Assessment Enabled by Digital Health Technologies

Retrieved on: 
Thursday, January 4, 2024
Data Management, Other Science, Practice Management, Physical Therapy, FDA, Technology, Research, Other Health, Surgery, Pharmaceutical, Oncology, Medical Devices, Hospitals, Genetics, Clinical Trials, Biotechnology, Software, Health, Science, Hardware, Continuity, Montefiore Medical Center, Influencer marketing, Clinical and Translational Science, PLOS, Informatics, Clinical trial, Cancer, Observational study, Elective surgery, JCO Clinical Cancer Informatics, Patient, Data collection, Protein, Vital signs, Area studies, Algorithm, Research fellow, Medical imaging

The paper, titled: “A Proposed Multi-Domain Digital Model for Capturing Functional Status and Health-Related Quality of Life in Oncology,” highlights the importance of collecting continuous 24/7 functional status measures digitally to enable better clinical decisions and outcomes assessment.

Key Points: 
  • The paper, titled: “A Proposed Multi-Domain Digital Model for Capturing Functional Status and Health-Related Quality of Life in Oncology,” highlights the importance of collecting continuous 24/7 functional status measures digitally to enable better clinical decisions and outcomes assessment.
  • However, the assessment of patients' functional status – encompassing physical, cognitive, and behavioral functioning – holds increasing significance in influencing clinical decisions and understanding treatment outcomes.
  • Koneksa's innovative digital model aims to address limitations in existing functional status assessments by leveraging digital health technologies (DHTs) for both objective and self-reported outcomes.
  • ”
    Continuous real-time digital monitoring of functional status can assess the health and well-being of patients in other diseases, such as in orthopedics.

New Study Reveals Important Insights on the Carbon Footprint of Beef Production

Retrieved on: 
Wednesday, December 13, 2023
Carbon footprint, Livestock, Research, Manure, UC, PLOS, Doctor of Philosophy, Breakthrough Institute, Breakthrough, Carbon, Climate, Economics, Soil

Many companies claim to sell carbon-neutral beef or reduce their carbon footprint by offering grass-fed alternatives.

Key Points: 
  • Many companies claim to sell carbon-neutral beef or reduce their carbon footprint by offering grass-fed alternatives.
  • Specifically, the study found that grass-fed beef operations had 20% higher emissions from production than grain-finished systems and a 42% higher carbon footprint overall when considering carbon sequestration and land use.
  • A 10% increase in beef production per acre was associated with a 4.8% decrease in emissions from production and a 9.0% decrease in carbon footprint, encompassing production emissions, soil carbon sequestration, and carbon opportunity cost.
  • According to co-author Linus Blomqvist “studies looking at the carbon footprint of beef have long been incomplete, often just including the production side and sometimes also accounting for carbon sequestration on grazing land.

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Retrieved on: 
Friday, December 1, 2023
Quality of life, Protein, GLB1, GM1, Disorder, PLOS, Brain, Muscle weakness, Doctor of Philosophy, Research, Therapy, Glycogen storage disease, Life expectancy, DSM-IV codes, Paratriathlon, Dystonia, Protein folding, Patient, HaloTag, Pharmaceutical industry

BETHESDA, Md., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the publication of preclinical data identifying a novel class of small molecule allosteric regulators that demonstrate therapeutic potential for galactosidase beta 1 (GLB1)-related lysosomal storage disorders (LSDs), including GM1 gangliosidosis. The study, “Validation of a highly sensitive HaloTag-based assay to evaluate the potency of a novel class of allosteric β-Galactosidase correctors,” was published in PLOS ONE.

Key Points: 
  • The study, “Validation of a highly sensitive HaloTag-based assay to evaluate the potency of a novel class of allosteric β-Galactosidase correctors,” was published in PLOS ONE.
  • GM1-gangliosidosis is an inherited, progressive disorder characterized by the degeneration of brain and spinal cord cells, leading to muscle weakness, skeletal abnormalities, dystonia, and vision problems.
  • Mutations in the GLB1 gene significantly reduce the activity and function of the lysosomal hydrolase enzyme β-galactosidase (β-Gal) due to protein misfolding.
  • Additionally, there are no available disease-modifying treatments for GM1 gangliosidosis, with available therapies only focused on reducing symptoms and improving quality of life.